DAY ONE BIOPHARMACEUTICALS, INC. Financials Day One Biopharmaceuticals, Inc.
Equities
DAWN
US23954D1090
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.92 USD | +12.94% |
|
-0.27% | +2.19% |
| Apr. 24 | Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating | MT |
| Apr. 24 | Transcript : Day One Biopharmaceuticals, Inc. - Special Call |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,044 | 1,583 | 1,271 | 1,304 | - | - |
| Enterprise Value (EV) 1 | 759.2 | 1,241 | 1,040 | 1,210 | 1,084 | 1,032 |
| P/E ratio | -3.65 x | -9.92 x | -6.16 x | -5.7 x | -7.55 x | -21.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 98.4 x | 15.1 x | 5.07 x |
| EV / Revenue | - | - | - | 91.3 x | 12.5 x | 4.01 x |
| EV / EBITDA | -10.5 x | -8.45 x | -5.05 x | -4.81 x | -4.9 x | 13.9 x |
| EV / FCF | -15.6 x | -11.3 x | -7.07 x | -6.12 x | -5.86 x | -15.6 x |
| FCF Yield | -6.39% | -8.86% | -14.1% | -16.3% | -17.1% | -6.41% |
| Price to Book | 3.71 x | - | 3.36 x | 4.57 x | 3.38 x | 3.6 x |
| Nbr of stocks (in thousands) | 61,929 | 73,550 | 87,043 | 87,377 | - | - |
| Reference price 2 | 16.85 | 21.52 | 14.60 | 14.92 | 14.92 | 14.92 |
| Announcement Date | 3/7/22 | 3/6/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 13.26 | 86.5 | 257.3 |
| EBITDA 1 | - | -72.54 | -146.8 | -206 | -251.7 | -221 | 74.34 |
| EBIT 1 | - | -72.74 | -146.9 | -206.1 | -242.4 | -194 | -40.39 |
| Operating Margin | - | - | - | - | -1,828.51% | -224.23% | -15.69% |
| Earnings before Tax (EBT) 1 | - | -72.75 | -142.2 | -188.9 | -226.7 | -148.9 | -37.06 |
| Net income 1 | -40.51 | -170.6 | -142.2 | -188.9 | -228.5 | -176.9 | -68.86 |
| Net margin | - | - | - | - | -1,723.55% | -204.5% | -26.76% |
| EPS 2 | -17.03 | -4.620 | -2.170 | -2.370 | -2.619 | -1.976 | -0.6870 |
| Free Cash Flow 1 | - | -48.54 | -109.9 | -147.1 | -197.6 | -185.1 | -66.11 |
| FCF margin | - | - | - | - | -1,490.97% | -214% | -25.69% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 5/4/21 | 3/7/22 | 3/6/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | 0.8904 | 4.406 | 8.683 | 19.71 |
| EBITDA | -19.24 | -21.92 | -27.74 | -36.71 | -39.66 | -42.73 | - | - | -51.43 | - | - | - | - | - | - |
| EBIT 1 | -19.24 | -21.98 | -27.75 | -36.72 | -39.7 | -42.74 | -45.86 | -49.25 | -51.44 | -59.52 | -59.83 | -63.57 | -59.79 | -58.26 | -47.3 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | -7,139.2% | -1,356.92% | -670.96% | -240% |
| Earnings before Tax (EBT) 1 | -19.24 | -21.94 | -27.75 | -36.53 | -37.8 | -40.11 | -42.39 | -45.86 | -46.15 | -54.51 | -57.3 | -59.54 | -56.04 | -53.29 | -45.6 |
| Net income 1 | -19.24 | -21.94 | -27.75 | -36.53 | -37.8 | -40.11 | -42.39 | -45.86 | -46.15 | -54.51 | -57.25 | -59.29 | -56.93 | -54.76 | -45.6 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | -6,659.19% | -1,291.93% | -630.68% | -231.38% |
| EPS 2 | -0.3300 | -0.3540 | -0.4800 | -0.6000 | -0.5300 | -0.5600 | -0.5900 | -0.6100 | -0.5400 | -0.6400 | -0.6625 | -0.6700 | -0.6425 | -0.6250 | -0.4850 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/7/22 | 5/12/22 | 8/4/22 | 11/7/22 | 3/6/23 | 5/1/23 | 8/7/23 | 11/6/23 | 2/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 284 | 342 | 231 | 93.4 | 219 | 272 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -48.5 | -110 | -147 | -198 | -185 | -66.1 |
| ROE (net income / shareholders' equity) | - | -150% | -46.4% | -55.7% | -85.7% | -42.5% | -8.68% |
| ROA (Net income/ Total Assets) | - | -102% | -44.5% | -52.1% | -67.9% | -38.9% | -7.83% |
| Assets 1 | - | 167.7 | 319.4 | 362.5 | 336.6 | 455.1 | 880 |
| Book Value Per Share 2 | - | 4.540 | - | 4.340 | 3.260 | 4.410 | 4.140 |
| Cash Flow per Share 2 | - | - | -1.680 | -1.840 | -0.4500 | -2.200 | - |
| Capex 1 | - | - | 0.03 | 0.22 | 4.03 | 4.22 | 4.43 |
| Capex / Sales | - | - | - | - | 30.37% | 4.88% | 1.72% |
| Announcement Date | 5/4/21 | 3/7/22 | 3/6/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
14.92
USD
Average target price
36.89
USD
Spread / Average Target
+147.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.19% | 1.3B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- DAWN Stock
- Financials Day One Biopharmaceuticals, Inc.
